1452228-33-9Relevant academic research and scientific papers
CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 0001101; 0001103; 0001190; 0001193, (2018/01/17)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.
DIHYDROPTERIDINONES II
-
Page/Page column 76, (2014/09/03)
The present invention relates to spiroheterocycl-dihydropyhmidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Αβ peptides.
DIHYDROPTERIDINONES II
-
Paragraph 0374-0376, (2013/09/12)
The present invention relates to spiroheterocycl-dihydropyrimidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides.
